USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
Verax Corp
Address:
Etna Rd Hc 61 Box 6
Lebanon, NH 03766
Phone:
N/A
URL:
N/A
EIN:
N/A
DUNS:
N/A
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $455,427.00 10
SBIR Phase II $640,930.00 2

Award List:

CONTINUOUS CELL CULTURE FOR MONOCLONAL ANTIBODIES

Award Year / Program / Phase:
1983 / SBIR / Phase I
Award Amount:
$43,073.00
Agency:
HHS
Principal Investigator:
Frederick Cahn
Abstract:
N/a

CONTINUOUS CELL CULTURE FOR MONOCLONAL ANTIBODIES

Award Year / Program / Phase:
1984 / SBIR / Phase II
Award Amount:
$434,930.00
Agency:
HHS
Principal Investigator:
Frederick Cahn
Abstract:
The objective for this project is to prove the feasibility of the research plan for a phase ii program to demonstrate a large cost reduction for the "in vitro" production of monoclonal antibodies. according to the applicant's company's system, hybridomas are immobilized in hydrocolloidgels or in… More

THE OBJECTIVE OF THIS PROJECT IS TO DEMONSTRATE THE FEASIBILITY OF EFFICIENTLY PRODUCING BIOCHEMICALS FROM MAMMALIAN FIBROBLASTS BY A NOVEL METHOD OF CONTINUOUS CULTURE WITH IMMOBILIZED CELLS.

Award Year / Program / Phase:
1985 / SBIR / Phase I
Award Amount:
$38,378.00
Agency:
HHS
Principal Investigator:
Philip g. phillips , PRINCIPAL INVESTIGATOR
Abstract:
The objective of this project is to demonstrate the feasibility of efficiently producing biochemicals from mammalian fibroblasts by a novel method of continuous culture with immobilized cells. the novelty of this method centers on a unique cell carrier, which allows for a high density of cell… More

THE OBJECTIVE OF THIS PHASE I PROJECT IS TO DEMONSTRATE THE FEASIBILITY OF A NOVEL APPROACH TO CULTURING CELLS IN ORDER TO PRECISELY DETERMINE THEIR RESPONSE TO ENVIRONMENTAL CHANGES.

Award Year / Program / Phase:
1985 / SBIR / Phase I
Award Amount:
$46,976.00
Agency:
HHS
Principal Investigator:
Philip g. phillips and su , PRINCIPAL INVESTIGATOR
Abstract:
The objective of this phase i project is to demonstrate the feasibility of a novel approach to culturing cells in order to precisely determine their response to environmental changes. this approach will allow for rapid optimization of culture conditions so that expression of a desired biochemical… More

MATHEMATICAL MODELING OF MAMMALIAN CELLS

Award Year / Program / Phase:
1985 / SBIR / Phase I
Award Amount:
$39,000.00
Agency:
NSF
Principal Investigator:
Nitya G Ray , Director Culture Kinetics Lab
Abstract:
N/a

THE CULTURE ENVIRONMENT IN WHICH A MAMMALIAN CELL IS MAINTAINED CAN PROFOUNDLY INFLUENCE ITS STATE OF DIFFERENTIATION AND ITS LONGEVITY AS WELL AS ITS GROWTH RATEAND PRODUCTIVITY.

Award Year / Program / Phase:
1986 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Edward g hayman , PRINCIPAL INVESTIGATOR
Abstract:
The culture environment in which a mammalian cell is maintained can profoundly influence its state of differentiation and its longevity as well as its growth rateand productivity. verax corporation has developed a system for the mass culture of mammalian cells and has chosen large-scale production… More

WITH THE ADVENT OF MONOCLONAL ANTIBODY TECHNOLOGY, TWO THINGS HAVE BECOME INCREASINGLY OBVIOUS: 1.

Award Year / Program / Phase:
1986 / SBIR / Phase I
Award Amount:
$47,000.00
Agency:
HHS
Principal Investigator:
Amar s tung , PRINCIPAL INVESTIGATOR
Abstract:
With the advent of monoclonal antibody technology, two things have become increasingly obvious: 1. these moleculeswill be needed in kilogram quantities for the treatment of avariety of malignancies. 2. antibodies of human, and not murine, origin will ultimately be the molecules of choice. verax has… More

THE USE OF IN VITRO PRODUCED MONOCLONAL ANTIBODIES FOR THE TREATMENT OF IMMUNOLOGIC, INFECTIOUS, AND NEOPLASTIC DISEASES IN HUMANS IS PROJECTED TO INCREASE SHARPLY IN THE UPCOMING YEARS.

Award Year / Program / Phase:
1986 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Amar s tung , PRINCIPAL INVESTIGATOR
Abstract:
The use of in vitro produced monoclonal antibodies for the treatment of immunologic, infectious, and neoplastic diseases in humans is projected to increase sharply in the upcoming years. verax corporation has developed a novel system for the mass culture of hybridoma cells as well as several… More

MATHEMATICAL MODELING OF MAMMALIAN CELLS

Award Year / Program / Phase:
1987 / SBIR / Phase II
Award Amount:
$206,000.00
Agency:
NSF
Principal Investigator:
Nitya G Ray , Director Culture Kinetics Lab
Abstract:
The recent development of molecular biology, particularly inthe field of recombinant dna technology, gives birth to a new era in medical therapeutics and diagnostics using products from mammalian cell culture. for effective research and clinical use, these products need to be manufactured in large… More

A NOVEL SYSTEM FOR HUMAN HYBRIDOMA CULTURE

Award Year / Program / Phase:
1987 / SBIR / Phase I
Award Amount:
$43,000.00
Agency:
HHS
Principal Investigator:
Amar s tung phd
Abstract:
With the advent of monoclonal antibody technology, it has become clear that there is a growing need to produce human cells and cell products in larger quantities for the treatment of various immunologic, infectious, and neoplasticdiseases. verax corporation has developed a novel system for the mass… More

DEFINED MEDIA FOR CONTINUOUS CULTURE OF MAMMALIAN CELLS

Award Year / Program / Phase:
1988 / SBIR / Phase I
Award Amount:
$48,000.00
Agency:
HHS
Principal Investigator:
Abstract:
With the advent of genetic engineering technology, it has become clear that there is a growing need to produce cloned cell products in larger quantities for the treatment of various cardiovascular, immunologic, infectious and neoplastic diseases. verax corporation has developed a novel system for… More

PRODUCTION OF HIV GP-120 PROTEIN

Award Year / Program / Phase:
1989 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Abstract:
The terminal nature of hiv infections has prompted demands for large quantities of hiv proteins for research related to understanding the virus and developing therapeutic treatments. verax corporation has developed a unique systemfor the mass culture of mammalian cells in a continuous fluidized bed… More